How it works, simply
It activates GLP-1 receptors to support the body's response to rising blood sugar.
What the evidence tells us
Diabetes evidence should not be presented as approval for general weight-loss use.
Watch with PEP 7
A short introduction; the sources and limitations remain important.
Open video guide
Video guides are coming soon.
Risks and open questions
- Gastrointestinal effects and hypoglycemia with certain diabetes medicines are relevant risks.
- The label has a thyroid C-cell tumor boxed warning and specific contraindications; the human tumor risk is uncertain.
Research and education only. PepGuide does not recommend medicines, doses or protocols.
Technical details and study context
Mechanism: Activates GLP-1 receptors to improve glucose-dependent insulin secretion.
Sponsor or developer: Eli Lilly and Company
Studied or labeled topics: Type 2 diabetes, Cardiovascular risk reduction
Commercial blend names and research vials do not inherit a medicine’s approval or manufacturing controls.
Sources and review dates
- DailyMed: TRULICITY prescribing information ↗ · Regulator · Aug 10, 2026
Product labels and further research
These directories help locate records. They are not individual studies supporting every statement.
Readability updated October 10, 2026. Evidence review: October 10, 2026 (linked label: purpose and selected risks). A wording update is not a new clinical review.